

CLAIMS AMENDMENTS

1. (Currently Amended) An implant ~~(10, 30, 40)~~ for releasing an active substance (22) into a vessel through which a body medium flows, ~~wherein the said~~ implant ~~(10, 30, 40)~~ comprising: ~~es~~ a basic body ~~(12, 32, 42)~~ ~~which consists of~~ comprising a biodegradable material as substrate for the active substance (22) to be released, and around which the body medium flows on the inside and/or outside.
2. (Currently Amended) The implant ~~according to of~~ Claim 1, ~~characterised in that wherein~~ the basic body ~~(12, 32)~~ ~~consists comprises~~ at least in ~~certain regions~~ part of a biodegradable material selected from the group consisting of magnesium, iron ~~or~~ tungsten alloy.
3. (Currently Amended) The implant ~~according to of~~ Claim 2, ~~characterised in that wherein~~ the ~~magnesium~~ alloy is an alloy of the type WE.
4. (Currently Amended) The implant ~~according to of~~ Claim 3, ~~characterised in that wherein~~ the ~~magnesium~~ alloy is an alloy of the type WE43.
5. (Currently Amended) The implant ~~according to of~~ Claim 2, ~~characterised in that wherein~~ the ~~magnesium~~ alloy ~~has a content~~ contains ~~of between~~ 1 and 30% by weight of lithium.
6. (Currently Amended) The implant ~~according to of~~ Claim 2, ~~characterised in that wherein~~ the ~~magnesium~~ alloy ~~has a content~~ contains ~~of between~~ 0.1 ~~to and~~ 10% by weight of aluminium.
7. (Currently Amended) The implant ~~according to of~~ Claim 2, ~~characterised in that wherein~~ the ~~magnesium~~ alloy ~~has a content~~ contains ~~of between~~ 0.01 ~~to and~~ 2% by weight of zirconium.
8. (Currently Amended) The implant ~~according to of~~ Claim 2, ~~characterised in that wherein~~ the ~~magnesium~~ alloy ~~contains one or a plurality of~~ comprises at least one alloy constituents selected from the group consisting of rare earth metals, yttrium, lithium, aluminium and zirconium.

9. (Currently Amended) The implant ~~according to any one of Claim 1 the preceding claims,~~ characterised in that wherein the basic body (12, 32) of the implant (10, 30) is designed so that it is able to ~~have~~comprises a first, non-expanded condition and a second, expanded condition.

10. (Currently Amended) The implant ~~according to any one of the preceding claims~~Claim 1, characterised in that wherein the basic body (12, 32) ~~has~~comprises:
 - a) a coating on at least certain regions on its sides facing the vessel; ~~at least in certain regions, a coating (24) and/or,~~
 - b) one or a plurality of at least one cavity;ies (26) and/or, and,
 - c) one or a plurality of at least one hollow body;ies (28),

which contain the active substance ~~(22).~~

11. (Currently Amended) The implant ~~according to of~~ Claim 1, characterised in that wherein the basic body (12, 32, 42) is tubular, cylindrical, spherical or reticulate.

12. (Currently Amended) ~~An application of an implant according to any one of Claims 1 to 11 for implant for~~ regional drug delivery (RDD), comprising: a basic body comprising a biodegradable material as substrate for the active substance to be released, and around which the body medium flows on the inside and/or outside.

13. (Currently Amended) The regional drug delivery implant of Claim 12, wherein said implant is used ~~application of an implant according to any one of Claims 1 to 11 for~~ tumour treatment.